SISTER Study: Improving Stroke Treatment Response with TS23

SISTER Study led by Eva Mistry aims to identify a safe and effective dose of TS23 for treating ischemic stroke patients with core-penumbra mismatch. The Phase-2 trial involves 300 adults and spans 54 months, with primary endpoints focusing on treatment efficacy and safety. The study is randomized, p

0 views • 22 slides